Jane Street
KPTI icon

Jane Street’s Karyopharm Therapeutics KPTI Stock Holding History

Jane Street’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$590K Buy
105,901
+70,368
+198% +$536K ﹤0.01% 7664
2025
Q4 		$262K Buy
+35,533
New +$217K ﹤0.01% 9140
2025
Q2 		– Sell
-11,420
Closed -$42.7K – 10304
2025
Q1 		$42.7K Sell
11,420
-38,467
-77% -$328K ﹤0.01% 9040
2024
Q4 		$506K Buy
49,887
+36,237
+265% +$438K ﹤0.01% 6756
2024
Q3 		$170K Sell
13,650
-89,682
-87% -$1.11M ﹤0.01% 8747
2024
Q2 		$1.34M Buy
103,332
+91,889
+803% +$1.52M ﹤0.01% 5199
2024
Q1 		$259K Sell
11,443
-6,921
-38% -$121K ﹤0.01% 7777
2023
Q4 		$238K Buy
+18,364
New +$247K ﹤0.01% 7968
2023
Q3 		– Sell
-44,158
Closed -$1.19M – 9035
2023
Q2 		$1.19M Buy
+44,158
New +$1.9M ﹤0.01% 4942
2023
Q1 		– Sell
-6,489
Closed -$320K – 9500
2022
Q4 		$331K Buy
6,489
+5,504
+559% +$382K ﹤0.01% 6851
2022
Q3 		$81K Sell
985
-12,921
-93% -$965K ﹤0.01% 8749
2022
Q2 		$941K Sell
13,906
-13,884
-50% -$1.27M ﹤0.01% 5582
2022
Q1 		$3.07M Buy
27,790
+13,980
+101% +$1.74M ﹤0.01% 3904
2021
Q4 		$1.33M Buy
13,810
+11,921
+631% +$1.19M ﹤0.01% 5334
2021
Q3 		$165K Buy
1,889
+93
+5% +$9.65K ﹤0.01% 8987
2021
Q2 		$278K Sell
1,796
-3,092
-63% -$449K ﹤0.01% 8281
2021
Q1 		$771K Buy
4,888
+157
+3% +$33.1K ﹤0.01% 5974
2020
Q4 		$1.1M Sell
4,731
-764
-14% -$177K ﹤0.01% 4498
2020
Q3 		$1.2M Sell
5,495
-1,673
-23% -$409K ﹤0.01% 3780
2020
Q2 		$2.04M Buy
+7,168
New +$2.12M ﹤0.01% 3041
2020
Q1 		– Sell
-996
Closed -$275K – 5680
2019
Q4 		$286K Sell
996
-432
-30% -$93.7K ﹤0.01% 4324
2019
Q3 		$206K Buy
+1,428
New +$194K ﹤0.01% 4617
2014
Q3 		– Sell
-942
Closed -$658K – 2833
2014
Q2 		$658K Buy
+942
New +$438K 0.01% 1204

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Jane Street's KPTI Position: Q1 2026 in Review

Jane Street increased its Karyopharm Therapeutics (KPTI) stake by 198% in Q1 2026, buying an estimated $536K and bringing the position to 105,901 shares worth $590K. The position accounts for ﹤0.01% of the portfolio, ranked #7664.

Jane Street first reported a position in KPTI in Q2 2014 and has held it in 23 quarters since. The position peaked at $3.07M in Q1 2022. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Jane Street held 105,901 shares of Karyopharm Therapeutics worth $590K as of Q1 2026.
  • Jane Street bought 70,368 Karyopharm Therapeutics shares in Q1 2026, an estimated $536K.
  • Karyopharm Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7664 holding.
  • Jane Street first reported a position in Karyopharm Therapeutics in Q2 2014 and has held it in 23 quarters since.
  • Jane Street's Karyopharm Therapeutics position peaked at $3.07M in Q1 2022.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.